<DOC>
	<DOCNO>NCT02479412</DOCNO>
	<brief_summary>This study randomise , double-blind , multiple dose ( 14 day ) , placebo-controlled , multi-center study ass efficacy safety three dose level AZD7594 , give daily inhalation , patient mild moderate asthma .</brief_summary>
	<brief_title>A Multiple Dosing ( 14 Days ) Study Assess Efficacy Safety Three Dose Levels AZD7594 , Given Once Daily Inhalation , Patients With Mild Moderate Asthma</brief_title>
	<detailed_description>This randomize , double-blind , multiple dosing ( 14 ± 1 day ) , placebo-controlled , incomplete block crossover , multi-center study assess efficacy safety 3 dose level AZD7594 , give daily inhalation , patient mild moderate asthma . This multi-center study conduct multiple site Europe . It plan approximately 48 patient mild moderate asthma randomize study</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Body mass index 18 35 kg/m2 Men woman 18 75 year age , inclusive Patients need nonsmoker exsmokers ( quit ≥ 6 month Visit 1 ) total smoke history &lt; 10 pack year Documented clinical diagnosis asthma ≥ 6 month Visit 1 Patients lowdose inhaled corticosteroid ( ICS ) ( equivalent budesonide ≤ 400 μg per day ) lowdose ICS/longacting β2 agonist ( LABA ) , inhaled steroid , patient montelukast Patients control low dose budesonide first 14 ±2 day Runin Part 1 , i.e. , need ACQ5 ≤ 1.5 Visit 2 . Prebronchodilator FEV1 Visit 3 40 % 90 % predict ( mean 2 predose measurement take 30 minute apart ) . All patient need FeNO concentration ≥ 25 part per billion Visit 3 Demonstrate ability use study inhalation device properly Women must nonchildbearing potential define meet 1 follow criterion : Permanently surgically sterilize , include hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy Postmenopausal ; age ≤ 50 year amenorrheic 12 month follow cessation exogenous hormonal treatment luteinizing hormone follicle stimulate hormone level postmenopausal range Postmenopausal ; age &gt; 50 year amenorrheic 12 month , follow cessation exogenous hormonal treatment Male patient willing use condom prevent pregnancy exposure female partner AZD7594 refrain donate sperm father child first day dose 3 month last dose IMP . Known suspect hypersensitivity IMPs excipients , include lactose Systemic steroid use 6 week Visit 1 Any active disease asthma Patients medium highdose ICS ( equivalent budesonide &gt; 400 μg per day ) inhale anticholinergic combination within 6 week prior Visit 1 Compliance eDiary least 80 % day expect Runin Treatment Periods . Patients &lt; 80 % eDiary compliance Runin Periods would randomize Treatment biologicals monoclonal antibody chimeric biomolecules include omalizumab within 6 month 5 halflives Visit 1 , whichever long History clinical suspicion clinically relevant disease disorder , opinion Investigator , may either put patient risk participation study , influence result patient 's ability participate study , safety concern opinion Investigator ACQ5 ≥ 3 time Visits 1 3 Any contraindication use vagolytic sympathomimetic drug judge Investigator . Patients hepatitis B surface antigen , hepatitis C virus antibody human immunodeficiency virus ( HIV ) Donation blood ( ≥ 450 mL ) within 3 month donation plasma within 14 day Visit 1 Pregnant woman nurse mother Suspicion Gilbert 's syndrome Vulnerable person ( e.g. , person keep detention ) ACQ5 ≥ 3 daily rescue use ≥ 12 puff ≥ 3 consecutive day enrollment period Hypersensitivity active substance excipients Runin medication ( i.e. , budesonide )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Mild moderate asthma</keyword>
	<keyword>FEV1</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>